Flow cytometry reveals the nuances of clonal haematopoiesis

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

“… 39 , 40 However, there is some evidence that preleukemic clonal hematopoiesis may persist in AML patients who are in complete remission without any genetic evidence of MRD, and that the aberrant blast phenotypes may represent preleukemic clonal hematopoiesis leading to their misidentification as MRD. 41 , 42 Age-matched controls are therefore preferred to avoid possible age-related differences in marker expression to be identified as LAIPs. Furthermore, it is essential to know how the surface marker expression may be modified in the recovery phase after chemotherapy or transplantation.…”

“…Furthermore, in older patients clonal hematopoiesis of indeterminate potential can occur, although its influence on differentiation antigens pattern is not fully elucidated 39,40 . However, there is some evidence that preleukemic clonal hematopoiesis may persist in AML patients who are in complete remission without any genetic evidence of MRD, and that the aberrant blast phenotypes may represent preleukemic clonal hematopoiesis leading to their misidentification as MRD 41,42 . Age‐matched controls are therefore preferred to avoid possible age‐related differences in marker expression to be identified as LAIPs.…”